Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.

Pataer, Apar

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. [electronic resource] - Cancer medicine 06 2018 - 2405-2414 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

2045-7634

10.1002/cam4.1505 doi


Adult
Aged
Aged, 80 and over
Female
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoadjuvant Therapy--methods
Rad51 Recombinase--genetics
Survival Rate